Solid Biosciences to Present at the Jefferies London Healthcare Conference
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
馬薩諸塞州查爾斯敦，2024年11月14日（GLOBE NEWSWIRE）——開發神經肌肉和心臟疾病精準基因藥物的生命科學公司固德生物科學公司（納斯達克股票代碼：SLDB）（「公司」 或 「Solid」）今天宣佈，總裁兼首席執行官Bo Combo和首席醫學官加布裏埃爾·布魯克斯萬博士將於2024年11月20日星期三出席傑富瑞倫敦醫療保健會議，格林尼治標準時間下午 1:30（美國東部時間上午 8:30）。
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演示文稿的網絡直播將在公司網站 「投資者」 部分的 「活動」 頁面上提供，也可以點擊此處觀看。網絡直播重播將在 「活動」 頁面存檔 30 天。
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.
有興趣在會議期間與管理層會面的機構投資者可以聯繫其傑富瑞代表。
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
關於固體生物科學
Solid Biosciences是一家精準遺傳醫學公司，專注於推進基因療法候選產品組合，包括用於治療杜興氏肌營養不良症（杜興納）的SGT-003、用於治療兒茶酚胺能多態性心室心動過速（CPVT）的SGT-501、用於治療BAG3介導的擴張型心肌病的AVB-401以及其他資產治療致命的心臟病。Solid 正在推進其針對罕見神經肌肉和心臟疾病的多元化產品線，彙集了科學、技術、疾病管理和護理領域的專家。Solid 以患者爲中心，由直接受影響的人創立，其使命是改善患有這些毀滅性疾病的患者的日常生活。欲了解更多信息，請訪問。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
固體生物科學投資者聯繫方式：
妮可安德森
投資者關係和企業傳播總監
固體生物科學公司
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫人：
格倫·西爾弗
FINN 合作伙伴
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
資料來源：固態生物科學公司
